Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2007 | 4.91 Million USD | -0.84% |
| 2006 | 4.95 Million USD | 51.91% |
| 2005 | 3.26 Million USD | -58.45% |
| 2004 | 7.85 Million USD | 175.74% |
| 2003 | 2.84 Million USD | 92.23% |
| 2002 | 1.48 Million USD | 0.0% |
| 1999 | 4.79 Million USD | -11.75% |
| 1998 | 5.43 Million USD | -7.06% |
| 1997 | 5.85 Million USD | 22.25% |
| 1996 | 4.78 Million USD | 36.75% |
| 1995 | 3.5 Million USD | 118.75% |
| 1994 | 1.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2007 Q1 | 2.55 Million USD | 39.54% |
| 2007 FY | 4.91 Million USD | -0.84% |
| 2007 Q4 | 1.14 Million USD | 113.01% |
| 2007 Q3 | 536.62 Thousand USD | 178.99% |
| 2007 Q2 | -679.38 Thousand USD | -126.56% |
| 2006 FY | 4.95 Million USD | 51.91% |
| 2006 Q1 | 1.55 Million USD | 63.45% |
| 2006 Q3 | 748.96 Thousand USD | -9.12% |
| 2006 Q4 | 1.83 Million USD | 144.78% |
| 2006 Q2 | 824.11 Thousand USD | -46.95% |
| 2005 Q4 | 950.37 Thousand USD | 29.8% |
| 2005 Q3 | 732.16 Thousand USD | 3.53% |
| 2005 Q2 | 707.17 Thousand USD | -19.21% |
| 2005 FY | 3.26 Million USD | -58.45% |
| 2005 Q1 | 875.33 Thousand USD | -34.95% |
| 2004 Q1 | 4.17 Million USD | 1413.45% |
| 2004 FY | 7.85 Million USD | 175.74% |
| 2004 Q4 | 1.34 Million USD | 34.22% |
| 2004 Q3 | 1 Million USD | -26.13% |
| 2004 Q2 | 1.35 Million USD | -67.46% |
| 2003 Q4 | 275.58 Thousand USD | -72.09% |
| 2003 FY | 2.84 Million USD | 92.23% |
| 2003 Q3 | 987.26 Thousand USD | 99.61% |
| 2003 Q1 | 569.39 Thousand USD | 0.0% |
| 2003 Q2 | 494.58 Thousand USD | -13.14% |
| 2002 FY | 1.48 Million USD | 0.0% |
| 2000 Q2 | 924.45 Thousand USD | -11.65% |
| 2000 Q1 | 1.04 Million USD | -15.29% |
| 1999 FY | 4.79 Million USD | -11.75% |
| 1999 Q4 | 1.23 Million USD | 14.72% |
| 1999 Q3 | 1.07 Million USD | 0.0% |
| 1998 FY | 5.43 Million USD | -7.06% |
| 1997 Q1 | 1.4 Million USD | 0.99% |
| 1997 FY | 5.85 Million USD | 22.25% |
| 1996 Q1 | 900 Thousand USD | -18.18% |
| 1996 Q2 | 1.1 Million USD | 22.22% |
| 1996 FY | 4.78 Million USD | 36.75% |
| 1996 Q3 | 1.4 Million USD | 27.27% |
| 1996 Q4 | 1.38 Million USD | -0.98% |
| 1995 Q2 | 900 Thousand USD | 28.57% |
| 1995 Q4 | 1.1 Million USD | 22.22% |
| 1995 Q3 | 900 Thousand USD | 0.0% |
| 1995 Q1 | 700 Thousand USD | 40.0% |
| 1995 FY | 3.5 Million USD | 118.75% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | 400 Thousand USD | 0.0% |
| 1994 Q4 | 500 Thousand USD | 25.0% |
| 1994 FY | 1.6 Million USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -268.264% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 2.462% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 83.359% |
| Nascent Biotech, Inc. | 2.22 Million USD | -120.546% |
| Rebus Holdings, Inc. | 664 Thousand USD | -640.65% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 86.8% |
| Qrons Inc. | 643.67 Thousand USD | -664.034% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1162.408% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 91.438% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1083.673% |
| Skye Bioscience, Inc. | 13.54 Million USD | 63.699% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.333% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1779.031% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.256% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -68.639% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -227.446% |
| Mesoblast Limited | 5.9 Million USD | 16.674% |
| Marizyme, Inc. | 19.23 Million USD | 74.439% |
| Genus plc | 147.7 Million USD | 96.67% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 43.982% |
| Pharming Group N.V. | 225.49 Million USD | 97.819% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -140.05% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -266.586% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 41.025% |
| ContraFect Corporation | 56.88 Million USD | 91.355% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -11.551% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -232.572% |
| IMV Inc. | 37.7 Million USD | 86.958% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -76.247% |
| MultiCell Technologies, Inc. | 567.42 USD | -866614.779% |
| ONE Bio Corp. | 6.44 Million USD | 23.681% |
| Accustem Sciences Inc. | 3.74 Million USD | -31.27% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.278% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -824.486% |
| Q BioMed Inc. | 3.43 Million USD | -43.103% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 80.102% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -87.169% |
| Biomind Labs Inc. | 994.18 Thousand USD | -394.669% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 95.049% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -179.478% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 26.795% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -163.784% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 19771.652% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 69.283% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -167.992% |
| GB Sciences, Inc. | 1.42 Million USD | -246.208% |
| Alpha Cognition Inc. | 9.7 Million USD | 49.329% |
| HST Global, Inc. | 140.9 Thousand USD | -3390.184% |
| CSL Limited | 3.44 Billion USD | 99.857% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -337.183% |
| Halberd Corporation | 74.84 Thousand USD | -6471.06% |
| Enzolytics Inc. | 2.17 Million USD | -125.643% |
| Agentix Corp. | 1.37 Million USD | -258.512% |
| Resverlogix Corp. | 12.71 Million USD | 61.313% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -34.711% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.679% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -371.064% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -104.493% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -211.387% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -44.433% |
| AVAX Technologies, Inc. | 7.31 Million USD | 32.726% |
| Zenith Capital Corp. | 8.94 Million USD | 45.008% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.404% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -28129.797% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -100.296% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2767.437% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -156.02% |
| Kadimastem Ltd | 2.41 Million USD | -104.053% |
| Helix BioMedix, Inc. | 1.97 Million USD | -149.383% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 54.745% |
| BioStem Technologies, Inc. | 22.97 Million USD | 78.594% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2609.818% |
| LadRx Corporation | 3.81 Million USD | -29.018% |
| Cell Source, Inc. | 4.32 Million USD | -13.7% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -432.524% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -432.524% |
| NovAccess Global Inc. | 2.46 Million USD | -99.367% |
| Affymax, Inc. | 39.38 Million USD | 87.514% |
| Itoco Inc. | 919.14 Thousand USD | -435.054% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -16.032% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -339.492% |
| Mobile Lads Corp. | 554.54 Thousand USD | -786.836% |
| CytoDyn Inc. | 18.05 Million USD | 72.766% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -19439.565% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2134.623% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -246.383% |
| SYBLEU INC | 160.87 Thousand USD | -2956.959% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -170.762% |
| International Stem Cell Corporation | 5.27 Million USD | 6.699% |
| Bioxytran, Inc. | 3.82 Million USD | -28.736% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -9242.185% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -24074.964% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 86.439% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -203.95% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -568.345% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -58.081% |
| Neutra Corp. | 243.82 Thousand USD | -1917.018% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 71.828% |
| PureTech Health plc | 144.59 Million USD | 96.599% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 75.998% |
| IXICO plc | 4.7 Million USD | -4.481% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 44.096% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 95.823% |
| CSL Limited | 3.89 Billion USD | 99.874% |
| Cellectis S.A. | 97.32 Million USD | 94.947% |